- Home
- REBN vs CVKD Comparison
REBN vs CVKD Comparison
Compare REBN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- CVKD
- Stock Information
- Founded
- REBN 2015
- CVKD 2022
- Country
- REBN United States
- CVKD United States
- Employees
- REBN N/A
- CVKD N/A
- Industry
- REBN Restaurants
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- REBN Consumer Discretionary
- CVKD Health Care
- Exchange
- REBN Nasdaq
- CVKD Nasdaq
- Market Cap
- REBN 8.6M
- CVKD 17.1M
- IPO Year
- REBN 2022
- CVKD 2023
- Fundamental
- Price
- REBN $2.30
- CVKD $14.45
- Analyst Decision
- REBN
- CVKD Strong Buy
- Analyst Count
- REBN 0
- CVKD 2
- Target Price
- REBN N/A
- CVKD $52.50
- AVG Volume (30 Days)
- REBN 24.3K
- CVKD 59.6K
- Earning Date
- REBN 11-12-2024
- CVKD 11-08-2024
- Dividend Yield
- REBN N/A
- CVKD N/A
- EPS Growth
- REBN N/A
- CVKD N/A
- EPS
- REBN N/A
- CVKD N/A
- Revenue
- REBN $5,757,858.00
- CVKD N/A
- Revenue This Year
- REBN $163.82
- CVKD N/A
- Revenue Next Year
- REBN $64.55
- CVKD N/A
- P/E Ratio
- REBN N/A
- CVKD N/A
- Revenue Growth
- REBN 42.94
- CVKD N/A
- 52 Week Low
- REBN $0.92
- CVKD $5.40
- 52 Week High
- REBN $8.80
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- REBN 31.36
- CVKD 56.80
- Support Level
- REBN $2.34
- CVKD $11.19
- Resistance Level
- REBN $2.87
- CVKD $17.95
- Average True Range (ATR)
- REBN 0.24
- CVKD 1.37
- MACD
- REBN 0.00
- CVKD 0.10
- Stochastic Oscillator
- REBN 21.22
- CVKD 49.64
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an innovative company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.